Intra‐arterial infusion therapy with 5‐(3,3‐dimeth yl‐1‐triazeno) imidazole‐4‐carboxamide (NSC 45388) for malignant melanoma

Lawrence H. Einhorn, Charles M. McBride, James K. Luce, Eulogio Caoili, Jeffrey A. Gottlieb

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Seventeen patients with advanced regional malignant melanoma were treated with intra‐arterial 5‐(3,3‐dimethyl‐1‐triazeno) imidazole‐4‐carboxamide (DTIC) in an attempt to improve the response rate to this drug. There were 6 partial objective (greater than 50% reduction) responders and one complete remission for an overall response rate of 41%. The local control of melanoma by this modality of treatment was impressive, and toxicity was less than that which is usually seen with systemic chemotherapy with DTIC. Our studies suggest intra‐arterial therapy is preferrable to systemic therapy for the isolated inoperable melanoma lesion.

Original languageEnglish (US)
Pages (from-to)749-755
Number of pages7
JournalCancer
Volume32
Issue number4
DOIs
StatePublished - Oct 1973
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intra‐arterial infusion therapy with 5‐(3,3‐dimeth yl‐1‐triazeno) imidazole‐4‐carboxamide (NSC 45388) for malignant melanoma'. Together they form a unique fingerprint.

  • Cite this